Does Coffee Count As Water? Here's What Experts Say
Hydration is a key part of a healthy body and mind. But with many of us starting our day with coffee, we could argue that a cup of joe is also a vital part of a functioning body and mind. According to Drive Research, 73% of people in the U.S. drink coffee every day, and 93% drink it at least once per week.
Between a love for hydration and coffee, you've probably wondered whether your daily cup counts toward your water intake. A black coffee, cold brew, or Americano is all water, right?
To get to the bottom of this, we consulted two health experts: Alex Larson, R.D.N., founder and CEO of Alex Larson Nutrition, and Dr. Raj Dasgupta, Chief Medical Advisor for Garage Gym Reviews.
Coffee drinkers, listen up. Both Larson and Dr. Dasgupta say yes, coffee can count toward your daily water intake.
"Even though caffeine can have a mild diuretic effect, the water in coffee usually makes up for it, especially if you're a regular drinker," Dr. Dasgupta says.
However, Larson adds that high amounts of caffeine might increase fluid loss for some people. This usually happens around 400mg or more of caffeine, or four or more cups of coffee per day.
In terms of how much caffeine is safe to drink, the FDA says up to 400mg of caffeine per day is "an amount not generally associated with negative effects."
The experts say other drinks like tea and soda also count toward hydration, but there are some caveats. Dr. Dasgupta says drinks high in sugar and additives, like soda and energy drinks, aren't the best way to hydrate.
"They're fine in moderation, but water and plain tea are better options," he says.
When it comes to staying hydrated, both Larson and Dr. Dasgupta recommend pairing coffee with water.
"A good rule of thumb is to pair each caffeinated beverage with a glass of water, especially around exercise or in hot weather," Larson says.
And how you start your day can make an impact, too.
"Starting your day with water, not just coffee, makes a big difference," Dr. Dasgupta says. He recommends keeping a water bottle nearby to sip on throughout the day.
You Might Also Like
Insanely Easy Weeknight Dinners To Try This Week
29 Insanely Delicious Vodka Cocktails
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
41 minutes ago
- Medscape
Study Shows Safety of Pharma-Grade CBD for Myocarditis
An oral formulation of pharmaceutically manufactured cannabidiol (CBD) that targets inflammatory pathways in myocarditis and pericarditis has been shown to be as safe as placebo in not elevating cardiovascular risks, results of a prospective trial have shown. The placebo-controlled trial enrolled 89 people with a history of cardiovascular disease (CVD) and/or at least one major risk factor for the condition who had been hospitalized for noncritical COVID-19. Leslie Cooper Jr, MD 'There are 45 or so who received pharmacologically produced CBD who had no increase in overall or cardiovascular adverse events, and in particular there was no prolongation of the QT interval,' Leslie Cooper Jr, MD, chair of cardiovascular medicine at Mayo Clinic Florida in Jacksonville, Florida, told Medscape Medical News . Cooper presented a poster on the study at Heart Failure Association of the European Society of Cardiology (HFA-ESC) 2025. The findings confirmed the safety of CBD doses up to 7.5 mg/kg twice daily used in the ARCHER trial in myocarditis and the MAVERIC trial in pericarditis, Cooper said. Study Shows Safety Signal The researchers designed the study during the COVID-19 pandemic to evaluate if people hospitalized for noncritical COVID-19 with a history of or a risk factor for CVD were also at an increased risk for cardiac inflammation, Cooper said. The study was stopped early because the pandemic ended. 'The findings were underpowered for efficacy, but they did support a safety signal,' he said. The study found no significant differences in adverse events between the CBD and no-CBD groups. For example, the rate of gastrointestinal disorders was 22.2% in the CBD group and 20.5% in the placebo group. Nervous system disorders were observed in 17.8% of CBD patients vs 18.2% of placebo patients. Eleven percent of CBD patients had respiratory, thoracic, and mediastinal disorders compared with 9% of placebo patients. The rates of cardiac adverse events were also similar between the two groups. No patients in the CBD group vs three (6.8%) of those in the placebo group had tachycardia. One case of atrial fibrillation, cardiac failure, left ventricular hypertrophy, and pericardial effusion was observed in the CBD group vs none in the placebo group. One patient in the placebo group vs none in the CBD group had atrial flutter. Most cases of myocarditis are mild and resolve spontaneously without long-term consequences, Cooper said. However, about 25% of cases have significant cardiovascular sequelae, including arrhythmias and heart failure. 'We know, based on clinical grounds, how to identify those complex patients who are probably going to have a rocky long-term course,' he said. New Treatments Needed While one drug, rilonacept (Arcalyst), has been approved for the treatment of recurrent pericarditis, no approved drugs for myocarditis exist. New treatments are also needed for cardiomyopathy. Bettina Heidecker, MD, head of Heart Failure and Cardiomyopathy at the German Charité Heart Center in Berlin, Germany, told Medscape Medical News , said current therapies such as corticosteroids and other immunosuppressants carry long-term risks such as osteoporosis, metabolic disorders, infections, and organ toxicity, 'A pharmaceutically standardized CBD formulation could offer a targeted anti-inflammatory approach with a more favorable side effect profile,' Heidecker told Medscape Medical News . 'This would be particularly beneficial for younger or lower-risk patients, or those in whom prolonged immunosuppression is problematic.' Heidecker said the new data provide a rationale for continued investigation of CBD in myocarditis and pericarditis. 'It will be exciting to investigate how individual patients respond to CBD, particularly early in the treatment course,' she said. Heidecker and her team in Berlin have been studying the utility of noninvasive magnetocardiography to detect myocardial inflammation and monitor response to anti-inflammatory therapy with the hope that the approach 'may help identify early responders and guide personalized treatment strategies with CBD.' The trial was funded by Cardiol Therapeutics. Cooper is a consultant to Cardiol Therapeutics. Heidecker holds patents for RNA-based diagnostics in myocarditis and holds pending patents on magnetocardiography for diagnosing cardiomyopathy. She reported financial relationships with Biomagnetik Park Hoilding, Pfizer, and AstraZeneca.
Medscape
an hour ago
- Medscape
Resistant Pneumonia Case Shakes Up Diagnostic Rules
A 61-year-old man presented with fever, dyspnoea, cough, and maculopapular rash. The patient had no relevant medical history. Laboratory tests revealed leucocytosis. A chest x-ray showed an infiltrate in the right lower lobe of the lung, which was confirmed by CT. However, antibiotics did not improve the condition. This rare case report by Ahmad B. Al-Zughoul, MD, a resident doctor of internal medicine, Saint Agnes Medical Center, Fresno, California, describes simultaneous bacterial ( Mycoplasma pneumoniae ), viral (coronavirus NL63), and fungal ( Coccidioides spp.) pneumonia in an immunocompetent adult. The Patient and His History The patient with no past medical history presented to the emergency department with a week-long history of skin rash, fever, and shortness of breath. The patient denied any preexisting medical conditions. On admission, the patient was febrile, with a body temperature of 38.8 °C. His heart rate was tachycardic at 115 beats/min. His respiratory rate was normal. Blood pressure and oxygen saturation in room air were within their respective normal ranges. Findings and Diagnosis Physical examination showed mild pharyngeal erythema, few coarse crackles at the lung bases, and a maculopapular rash on the trunk, shoulders, and upper thighs. Laboratory findings showed leukocytes with 15.0 × 103/μL (reference range, 4.5-11.0 × 103/μL), neutrophilia of 12.22 × 103/μL (reference range, 2.6-8.2 × 103/μL), and mild eosinophilia of 0.36 × 103/μL (reference range, 0.00-0.35 × 103/μL). A multiplex polymerase chain reaction respiratory panel called BioFire, which screens for both common viral and bacterial pathogens, was performed on a nasopharyngeal swab sample, and it was positive for M pneumoniae and coronavirus. Initial immunoglobulin M (IgM) and immunoglobulin G (IgG) enzyme immunoassays for Coccidioides spp. were negative, despite the patient's residence in an endemic area. A chest x-ray revealed a right lower lung infiltrate, which was confirmed by chest as well, which did not reveal pleural effusion or lymphadenopathy. Suspecting community-acquired pneumonia, clinicians initiated 500 mg intravenous (IV) daily and ceftriaxone 1 g IV daily. After 48 hours of IV antibiotics, the patient remained symptomatic with cough and fever, and leucocytosis persisted, although the skin rash was improving. He was started on levofloxacin 750 mg IV daily to cover the possibility of macrolide-resistant M pneumoniae . The patient was still having a cough and fever 5 days into admission, with a high total white blood cell count of 17.5 × 103/μL and an increased eosinophil count of 1.08 × 103/μL. Repeat Coccidioides IgM and IgG assays then returned positive. Following the infectious disease consultation, oral fluconazole (200 mg daily) was prescribed. The patient's symptoms and blood cell counts normalised rapidly with this regimen. Discussion 'This case report sheds light on how the presence of multiple respiratory pathogens can potentially complicate the clinical course and management of pneumonia in such patients. Clinicians should be aware of the sensitivity and specificity of microbiological tests used to diagnose specific respiratory pathogens in their institution to make informed management decisions for their patients. Consultation with infectious disease specialists can be very helpful as well in complicated or difficult cases or cases not responding to appropriate management,' the study authors wrote.
Yahoo
an hour ago
- Yahoo
Student saved by USD 428 staff after swallowing a pop lid
Jun. 10—When an Eisenhower Elementary student accidentally swallowed the small metal circle from his pop can lid, three staff members saw his distress and went into action. At the June 9 USD 428 Board of Education meeting, Kelsey Strickland, Abigail Jonas and Cyleigh Unruh received the district R.O.S.E. award, Recognizing Outstanding Support of Education. School Board President Jacquie Disque read the description of what happened one month earlier. During lunchtime on Friday, May 9, a student was showing signs of distress and music teacher Kelsey Strickland immediately came to his aid. "She determined that the student accidentally swallowed the lid of a pop can, which was lodged in the student's throat." Strickland then ran to get assistance from Cyleigh Unruh, the school nurse, and Abigail Jonas, the principal. They tended to the student, kept him calm, and made sure he got immediate medical attention. "The student was taken to the emergency room and, upon evaluation, required a surgical procedure to remove the pop can lid from their esophagus. Thanks to the quick thinking and actions of these district staff, the student received prompt medical care and has made a complete recovery without any serious injuries." Board member Aaron Emerson joined Superintendent Khris Thexton in presenting the award, revealing the fact that the student in distress was his son. The metal disc from the pop can has been framed and his son no longer drinks sodas from "pop tops," Emerson said. "We're glad you were there," Disque told the staff members.
